The acquisition also covers K-V Pharma’s certain packaging, manufacturing and laboratory facilities including certain intellectual property, existing and future product opportunities, as well as equipment specific to the generic business.
Furthermore, K-V Pharma has signed a supply deal with Zydus Pharma to offer third-party manufacturing services for Gynazole-1 and Clindesse.
Nesher CEO Greg Divis said they will continue working towards making important progress with Makena, returning their branded anti-infective products back to market and supporting additional growth potential for Evamist.